RecruitingNCT07419893

Germline Genetic Testing of the TP53 Gene

Germline Genetic Testing of the TP53 Gene: Identification, Characterization, and Management of Patients and Families at High Risk of Cancer


Sponsor

European Institute of Oncology

Enrollment

1,940 participants

Start Date

Jan 29, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

This is a retrospective, observational, single-center study designed as a cohort analysis. The study population will include consecutive patients referred for genetic counseling and TP53 germline genetic testing between 2004 and 2025 at the Division of Cancer Prevention and Genetics of the IEO. The primary endpoint is to determine the overall detection rate of Pathological Variants (PVs) in the TP53 gene among individuals referred to the institute and the differences between the groups.


Eligibility

Min Age: 18 YearsMax Age: 90 Years

Inclusion Criteria3

  • Have undergone at least one genetic counseling session at the Division of Cancer Prevention and Genetics of the IEO;
  • Have undergone germline TP53 genetic testing, regardless of the referral criteria for counseling and/or testing or the approach used;
  • Have provided written informed consent for participation in scientific research.

Exclusion Criteria1

  • Absence of signed informed consent for participation in scientific research.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Istituto Europeo di Oncologia

Milan, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07419893


Related Trials